Stockscreener 앱 받기
9.255
1.07%
-0.085
전일 마감가:
$9.34
열려 있는:
$9.33
하루 거래량:
1.11M
Relative Volume:
0.07
시가총액:
$10.61B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-2.9196
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+1.32%
1개월 성능:
+6.09%
6개월 성능:
-24.75%
1년 성능:
-10.98%
1일 변동 폭
$9.22
$9.37
1주일 범위
$8.88
$9.405
52주 변동 폭
$6.85
$13.55
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.25 | 10.61B | 14.33B | -3.79B | 1.84B | -3.17 |
|
RGC
Regencell Bioscience Holdings Ltd
|
22.79 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
158.80 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.23 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.02 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Andrew Smith Reports 2.90% Stake In Smarter Web Company As At June 13 Vs Prior Stake Of 10.39% - MarketScreener
Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, - openPR.com
Viatris Inc’s Mixed Bag: Down -29.49% in 6 Months, Down 2.28% in 30 Days - investchronicle.com
3 Reasons to Avoid VTRS and 1 Stock to Buy Instead - Yahoo Finance
Viagra ‘Make Love Last’ wins Pharma Grand Prix after artfully working around Chinese ad regulations - Ad Age
ViatrisMAKE LOVE LAST59s - Ad Age
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Viatris Announces Q2 2025 Earnings Call: Key Details for Investors Released - Stock Titan
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris - sharewise
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Transcript : Viatris Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - marketscreener.com
Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of Viatris (VTRS) with Neutral Recommendation - Nasdaq
Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout - Insider Monkey
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga
Goldman Sachs Initiates Coverage on Viatris (VTRS) with Neutral Rating | VTRS Stock News - GuruFocus
Goldman Sachs starts Viatris stock coverage with neutral rating - Investing.com
Transcript : Viatris Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - marketscreener.com
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals And Viatris - Barchart.com
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VTRS - TradingView
Class Action Lawsuit Filed: Viatris Inc. (VTRS)Join by June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
June 3, 2025 Deadline Approaching: Join Class Action Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris (VTRS) Reports Positive Phase 3 Trial Results for Night Driving Treatment - GuruFocus
Viatris sees positive top-line phase 3 results for night driving impairment asset - Seeking Alpha
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewswire
June 3, 2025 Deadline: Join Class Action Lawsuit Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming DeadlinesVTRS - FinancialContent
Viatris reports success in phase 3 trial of night vision treatment MR-142 - Investing.com India
Viatris (VTRS) Reports Positive Results from LYNX-2 Trial for Eye Treatment | VTRS Stock News - GuruFocus
VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris - GlobeNewswire
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - PR Newswire
Shareholders of Viatris Inc. (VTRS): Protect Your Rights Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Viatris Inc. (VTRS)June 3, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with ... - Bluefield Daily Telegraph
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action – VTRS - TradingView
Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Lost Money on Viatris Inc. (VTRS)? Urged to Join Class Action Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - StreetInsider
Did You Lose Money on Viatris Inc. (VTRS)? Levi & Korsinsky Urges Investors to Act Before June 3, 2025 - Stockhouse
VTRS CLASS NOTICE: Viatris Inc. Investors may have been - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - marketscreener.com
VIATRIS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc.VTRS - Business Wire
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
비아트리스 주식 (VTRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Le Goff Corinne | Chief Commercial Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
41,112 |
0 |
60,441 |
| FINNEY ELISHA W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
37,832 |
| Le Goff Corinne | Chief Commercial Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
37,894 |
0 |
36,721 |
| Campbell Paul | See Remarks |
Mar 04 '25 |
Option Exercise |
0.00 |
207,325 |
0 |
328,250 |
| Campbell Paul | See Remarks |
Mar 03 '25 |
Option Exercise |
0.00 |
19,348 |
0 |
144,590 |
| Vivaldi Coelho Rogerio | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
21,691 |
0 |
21,691 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
96,431 |
0 |
266,825 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
146,700 |
0 |
221,178 |
| PARRISH MARK W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
140,395 |
| Lyons Dillon JoEllen | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
77,691 |
0.28%
0.20%
자본화:
|
볼륨(24시간):